Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m²

Moleculin Biotech, Inc., (Nasdaq: 

Read the full article here

Related Articles